NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · IEX Real-Time Price · USD
22.57
+0.60 (2.73%)
May 2, 2024, 4:30 PM EDT - Market closed
NAMS Employees
NewAmsterdam Pharma Company had 29 employees on December 31, 2023. The number of employees increased by 12 or 70.59% compared to the previous year.
Employees
29
Change
12
Growth
70.59%
Revenue / Employee
$539,847
Profits / Employee
-$6,779,195
Market Cap
2.01B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Nov 22, 2022 | 17 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Amneal Pharmaceuticals | 7,700 |
| Galapagos NV | 1,123 |
| agilon health | 1,117 |
| Agios Pharmaceuticals | 386 |
| RxSight | 374 |
| Sana Biotechnology | 328 |
| Rocket Pharmaceuticals | 268 |
| Avadel Pharmaceuticals | 154 |
NAMS News
- 23 days ago - NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease - GlobeNewsWire
- 23 days ago - BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors - Business Wire
- 4 weeks ago - NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer - GlobeNewsWire
- 5 weeks ago - NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewsWire